DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the final topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (MVP-S, formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.
Read MoreMONTRÉAL, Aug. 2, 2021 /CNW Telbec/ - The Fonds de solidarité FTQ is proud to announce an investment to support an ownership transfer of the French company EMKA Technologies ("EMKA") to Québec engineer and entrepreneur David Brunet. Mr. Brunet, who managed the Canadian subsidiary of the SCIREQ group, will take over the reins at EMKA as president and CEO on August 2.
Read MoreTORONTO, MONTREAL, VANCOUVER, BC and BOSTON, July 26, 2021 /CNW/ - Lumira Ventures today announced a significant expansion of its capital base to support the founding and building of innovative healthcare companies in Canada and the U.S. The closing of the oversubscribed Lumira Ventures IV at US$220 million represents the largest fund Lumira has raised to date, and the largest institutional life sciences venture capital fund ever raised in Canada. In parallel, Lumira closed a strategic venture fund in partnership with an international pharmaceutical company. Collectively, the new funds represent over US$255 million (C$321 million) of committed capital.
Read MoreGénome Québec announced today a total investment of $18.4 million in innovative projects on the environment. The Board of Directors of Genome Canada approved funding for eight Canadian projects under the Genomic Solutions for Natural Resources and the Environment competition with a budget allocation of $58.6 million. Six of the eight projects involve Québec researchers, which means Québec is receiving 31% of the overall budget available nationwide
Read MoreSHERBROOKE, QC, Canada – July 20, 2021 – Imeka, the leading neuroimaging company combining diffusion imaging and AI to map white matter integrity, today announced a partnership with INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease. Imeka’s novel biomarker technology is being utilized in clinical trials evaluating INmune Bio’s lead drug candidate, XPro1595, as an investigational treatment for Alzheimer’s Disease. (…)
Read MoreMONTREAL, July 20, 2021 /PRNewswire/ -- NIMIUM Therapeutics (www.nimium.ca), a Montreal-based biotech, has formed a partnership with Paraza Pharma (www.parazapharma.com) to develop a new treatment for cardiometabolic diseases (CMDs). The treatment aims to prevent and reverse the adverse effects of excess sugar and caloric intake and to promote healthier aging. The partnership will focus on the early-stage development of glycerol-3-phosphate phosphatase (G3PP) activators.
Read MoreQuebec City, 14-07-2021—DIEX Research, a world-class Quebec-based company that conducts high-quality clinical research, is currently involved in the development of an experimental treatment for “fatty liver disease,” or non-alcoholic fatty liver disease, which affects as many as one in five Canadians, including a growing number of children.
Read MoreMONTREAL, July 13, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that it has entered into a licensing agreement with Astellas Pharma Inc. through its US subsidiary, Astellas Institute for Regenerative Medicine, for the in vitro use of the UM171 compound and certain other molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.
Read MoreMontréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver tissue to treat liver disease. Founded in 2018 to develop ReLiver®, a highly innovative platform technology which has shown immense promise in animal models to restore liver function, treat complications and accelerate liver regeneration, Morphocell has the potential to revolutionize the treatment of liver failure and save patient lives.
Read MoreMONTREAL, July 6, 2021 /CNW/ - A new made-in-Canada life sciences company, Nimium Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases.
Read MoreLAVAL, QC, June 30, 2021 /CNW Telbec/ - A few weeks after announcing the availability of its Elecsys® Anti-SARS-CoV-2-S (spike protein) antibody test, Roche Diagnostics, a division of Hoffmann-La Roche Limited, is pleased to announce that its SARS-CoV-2 Rapid Antigen Test Nasal, commercialized under a Global partnership with SD Biosensor Inc., has received approval under Health Canada's Interim Order, increasing Roche's contribution to the fight against the pandemic.
Read MoreMONTREAL--(BUSINESS WIRE)--Giiant Pharma inc. announced today that is closed an additional financing of $750,000 from AQC Capital (AQC) and $500,000 from CQDM for a total of $1.25 million.
Read MoreMONTREAL--(BUSINESS WIRE)--My Intelligent Machines (“MIMs”), a leader in artificial intelligence and systems biology, today announced it has received the Company of the Year 2021 Award by Anges Québec, during their 2021 Annual Gathering which brought together virtually close to 175 participants on June 3rd.
Read MoreMONTRÉAL, May 21, 2021 /CNW Telbec/ - The Fonds de solidarité FTQ is investing $3 million in Giiant Pharma, a Montreal-based preclinical biotech firm that today announced the closing of $13.5 million in financing.
Read MoreMONTRÉAL, QUÉBEC (May 25, 2021) – EVAH Corp. (EVAH or the Company) today announced the signing of four contracts with Elanco Animal Health Incorporated (NYSE: ELAN, Elanco) to acquire and develop technologies in animal health. EVAH is a biotechnology company specializing in the development of biologicals to help prevent bacterial diseases in food animals and microbiome solutions for growth performance.
Read MoreLaurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of hospitalized patients with COVID-19. The study, which enrolled 240 patients across Canada and United States, is expected to report top-line results in Q3 2021.
Read MoreQUEBEC CITY and LONDON, May 18, 2021 /CNW/ - Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago's plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK's pandemic adjuvant. These results are part of the ongoing Phase 2/3 study and reiterate the promising profile observed during Phase 1 testing. Immunogenicity, as measured by the neutralizing antibody titer, was high - about 10 times higher than those in a panel of sera from patients recovering from COVID-19. No related severe adverse events were reported and reactogenicity was generally mild to moderate and short in duration.
Read MoreCALGARY, AB, May 17, 2021 /CNW/ - adMare BioInnovations ("adMare") and AazeinTx Inc. ("AazeinTx") have closed a global exclusive licensing transaction for a promising acute asthma treatment.
Read MoreMONTREAL, May 12, 2021 /CNW/ - The Quebec – Clinical Research Organization in Cancer (Q-CROC) and Colorectal Cancer Canada (CCC) are partnering to endeavour to improve access to colorectal cancer clinical trials in Quebec.
Read More
